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Abstract 
Background: Organ dysfunction scores, based on physiological parameters, have been created to describe organ 
failure. In a general pediatric intensive care unit (PICU) population, the PEdiatric Logistic Organ Dysfunction-2 score 
(PELOD-2) score had both a good discrimination and calibration, allowing to describe the clinical outcome of critically 
ill children throughout their stay. This score is increasingly used in clinical trials in specific subpopulation. Our objec-
tive was to assess the performance of the PELOD-2 score in a subpopulation of critically ill children requiring plasma 
transfusions.
Methods: This was an ancillary study of a prospective observational study on plasma transfusions over a 6-week 
period, in 101 PICUs in 21 countries. All critically ill children who received at least one plasma transfusion during the 
observation period were included. PELOD-2 scores were measured on days 1, 2, 5, 8, and 12 after plasma transfusion. 
Performance of the score was assessed by the determination of the discrimination (area under the ROC curve: AUC) 
and the calibration (Hosmer–Lemeshow test).
Results: Four hundred and forty-three patients were enrolled in the study (median age and weight: 1 year and 9.1 kg, 
respectively). Observed mortality rate was 26.9 % (119/443). For PELOD-2 on day 1, the AUC was 0.76 (95 % CI 0.71–
0.81) and the Hosmer–Lemeshow test was p = 0.76. The serial evaluation of the changes in the daily PELOD-2 scores 
from day 1 demonstrated a significant association with death, adjusted for the PELOD-2 score on day 1.
Conclusions: In a subpopulation of critically ill children requiring plasma transfusion, the PELOD-2 score has a lower 
but acceptable discrimination than in an entire population. This score should therefore be used cautiously in this 
specific subpopulation.
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Background
Mortality is a frequent outcome in clinical trials in criti-
cally ill adults [1–5]. However, as mortality is lower in 
pediatric intensive care unit (PICU) patients [6–8], other 
outcome measures have been developed. Multiple organ 
dysfunction syndrome (MODS), frequently observed in 
PICU, is a good candidate marker of severity of illness 
because MODS is the main cause of death in adult ICU 
[9] and in PICU patients [7]. MODS scores can be used 
to assess the presence and severity of organ dysfunction 
on admission and throughout the stay [9].
In a general PICU population, the PEdiatric Logistic 
Organ Dysfunction-2 score (PELOD-2) and the daily 
PELOD-2 scores had both a good discrimination and 
calibration, allowing to describe the clinical outcome of 
critically ill children throughout their stay [8, 10].
Little is known regarding plasma use in children. Our 
recent international observational study shows that non-
bleeding patients represent more than half of the critically 
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ill children receiving plasma transfusions [11]. This marked 
heterogeneity in plasma transfusion patterns might be due 
to the absence of randomized controlled trials (RCTs) that 
could guide plasma transfusion strategies [12].
The first version of the PELOD score [7] has been 
used over the last few years as an outcome measure in 
studies in specific subpopulations, such as sepsis [13], 
hematopoietic stem cell transplant [14], acute respira-
tory dysfunction syndrome [15], extracorporeal life sup-
port [16], drowning [17], or seizure [18]. However, some 
authors have voiced their concern regarding using organ 
dysfunction scores in specific subpopulations [9].
Our hypothesis was that the PELOD-2 score would 
have the same performance in the subpopulation of 
patients receiving at least one plasma transfusion, vali-
dating its use as a surrogate outcome in a future RCT.
Our objective was to assess the performance of the 
PELOD-2 score in a subset of critically ill children requir-
ing plasma transfusions [11] during their PICU stay.
Methods
Study sites and population
This is an ancillary study of a large point-prevalence study 
conducted in 101 PICUs in 21 countries. The complete 
methods have already been published elsewhere [11].
In brief, six 1-week periods were randomly predefined 
over six consecutive months (April to September 2014) 
for each study site. All critically ill children aged 3 days 
to 16 years old admitted to a participating PICU on one 
of the study days were considered eligible. Any eligible 
patient for whom at least one plasma transfusion was 
administered on any study day was included unless one 
of the exclusion criteria (i.e., plasmapheresis and gesta-
tional age less than 37 weeks at the time of PICU admis-
sion) was present. If a patient was readmitted within 24 h 
of PICU discharge, this was considered part of the same 
admission.
Variable of interest
The primary variable of interest of this analysis is the 
daily PELOD-2 scores [8, 10]. This score evaluates five 
organ functions using ten items: neurologic (Glasgow 
coma score and pupillary reaction), cardiovascular (lac-
tatemia, mean arterial pressure), renal (creatinine), res-
piratory (PaO2/FiO2 ratio, PaCO2, invasive ventilation), 
and hematologic (white blood cell count and platelets). 
Data were collected on days 1 (i.e., the day of first trans-
fusion), 2, 5, 8, and 12. These time points were previously 
identified as the first optimal time points to estimate the 
daily PELOD-2 scores [8, 10].
As for previously published severity and MODS scores, 
the most abnormal value of each variable observed dur-
ing each of these time points was considered to calculate 
the PELOD-2 score. No laboratory tests were performed 
solely to meet the needs of this research; as recom-
mended, a non-collected value was considered normal 
[8].
We also collected demographic data and PICU mortal-
ity, our primary outcome, which was censored 28  days 
after the end of the enrollment period.
Ethics approval
Ethics committees or boards at all 101 sites approved this 
study.
Statistical analysis
Descriptive statistics are reported as mean  ±  standard 
deviation (SD), median and interquartile range (IQR), or 
proportions with their 95 % CI.
The association between PELOD-2 score and death 
was assessed by comparing the PELOD-2 score between 
survivors and non-survivors with a Mann–Whitney test. 
We also tested this association, adjusting for the baseline 
risk (PELOD-2 score at day 1) and the daily change in 
PELOD-2 score using a logistic regression model [10].
Discrimination refers to the ability of the score to sepa-
rate non-survivors from survivors across the whole group 
[19]. We calculated the area under the receiver operating 
characteristic curve (AUC) of the PELOD-2 scores with 
its 95 % CI, for each time point. It is usually considered 
that an AUC of 1, 0.90–0.99, 0.80–0.89, 0.70–0.79, 0.60–
0.69, and <0.60 is considered to be perfect, excellent, very 
good, good, moderate, and poor, respectively [20].
The calibration was assessed by directly comparing 
the observed and customized predicted mortality across 
subcategories of risk. We employed the Hosmer–Leme-
show goodness-of-fit test, where a p value >0.05 indicates 
acceptable calibration [20].
All tests were two sided, with an alpha level of 0.05. All 
statistical analyses were performed with SPSS version 20 
for Mac (SPSS, Chicago, IL, USA).
Results
Population
Over the 30 study days, 13,192 patients were admitted 
and hence eligible and 443 (3.4  %) critically ill children 
receiving at least one plasma transfusion were included. 
The center which included the largest number of patients 
contributed to 11.1 % (49/443) of the results. Two hun-
dred and fifty-three patients were from Europe, 134 from 
North America, and 56 from other continents.
The median age and weight were 1 year (IQR 0.2–6.4) 
and 9.1  kg (IQR 4.0–21.0), respectively. Forty-three 
percent were males. The main reasons for admission 
to PICU were respiratory (32  %), cardiac surgery with 
bypass (30  %), elective surgery (24  %), septic shock 
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(15  %), emergency surgery (13  %), cardiac non-surgical 
(11  %), renal failure (10  %), and hepatic failure (10  %). 
Forty-eight patients (11  %) were on extracorporeal life 
support, and 35 patients (8 %) were on continuous renal 
replacement therapy. The full demographic description is 
available elsewhere [11].
The primary indication for plasma transfusion was crit-
ical bleeding in 22 % of patients, minor bleeding in 21 %, 
planned surgery or procedure in 12  %, and high risk of 
postoperative bleeding in 11 %. No bleeding or planned 
procedures were reported in 34 % of patients.
Median length of mechanical ventilation was 5 days (IQR 
1–16), and median PICU length of stay was 10 days (IQR 
4–24). The median time to death was 6 days (IQR 1;17).
PELOD‑2 score
PELOD-2 score was collected in all patients on day 1 and 
in all surviving patients still in the PICU at posttransfu-
sion days 2, 5, 8, and 12. There were no missing data.
Median PELOD-2 scores were statistically different 
between survivors and non-survivors: 7 (5;9) versus 10 
(7;15) on transfusion day 1 (p < 0.001), as well as on the 
other days (Table 1; Fig. 1).
The PELOD-2 score on day 1 was a significant prog-
nostic factor: The odds ratio for death was 1.30 (95 % CI 
1.22–1.39) for each PELOD-2 point. Similarly, the serial 
evaluation of the changes in the daily PELOD-2 scores 
from day 1, adjusted for baseline value (PELOD-2 at day 
1), demonstrated a significant association with death, for 
each of the observation days (Table 2).
Discrimination
The AUC was 0.76 (95  % CI 0.71–0.81, Fig.  2) for day 
1 and 0.78, 0.74, 0.74, and 0.77, for days 2, 5, 8, and 12, 
respectively (Table  3). Adding the INR to the PELOD-2 
score resulted in an AUC of 0.77 (95 % CI 0.71–0.83). The 
AUC on day 1 according to plasma transfusion indication 
and according to the reason for admission is presented in 
Tables 4 and 5, respectively.
Calibration
The Hosmer–Lemeshow Chi-square value was 5.02 
(p =  0.76) for PELOD-2 score on day 1. The results for 
the other time points, according to plasma transfusion 
indication, and according to the reason for admission are 
given in Tables 3, 4, and 5, respectively.
Adding the INR to the PELOD-2 score resulted in Hos-
mer–Lemeshow Chi-square value of 10.6 (p = 0.23).
Discussion
Our results indicate that in a subpopulation of critically 
ill children requiring plasma transfusions, the PELOD-2 
score has an acceptable performance. These results of 
performance of the PELOD-2 scores are observed with 
the performance both according to the indications to 
plasma transfusion (Table 4) and according to the 5 days 
of the PELOD-2 scores (Tables 2, 3).
The PELOD-2 score seems to have a lower, although 
acceptable discrimination power compared to a general 
PICU population, where it had an excellent discrimina-
tion power, based on an AUC of 0.93. As the PELOD-2 
score has been advocated to be “used as a surrogate out-
come measure in randomized clinical trials” [7, 8], many 
recent trials have used these scores to assess patients 
[13–18]. As these studies enrolled only specific PICU 
subpopulations, their results should be interpreted cau-
tiously, in light of our findings. Similar caveats have been 
made for adult organ dysfunction scores regarding their 
use in specific subpopulations [9].
The lower discrimination of the PELOD-2 score in a 
subset of critically ill children transfused with plasma 
might be explained by different observations. First, our 
population was sicker than the initial PELOD-2 study, 
with a mortality rate of 26.9 versus 6.0  %. The PICU 
length of stay was also longer (10 vs. 2 days), as the case-
mix was different: In our population compared to the 
PELOD-2 population, the reasons for admission were 
less frequently respiratory (32 vs. 47  %, p  <  0.001) and 
more frequently cardiovascular (64 vs. 19 %, p < 0.001) or 
hepatic (10 vs. 1 %, p < 0.001) [8]. Moreover, in the study 
of Pollack et  al. (10,078 patients from U.S. PICUs), the 
mortality rate was 2.7 %, with a median age of 3.7 years 
and a median hospital length of stay of 4.9  days (PICU 
length of stay was not provided) [21]. The fact that all 
patients received plasma transfusions might also explain 
Table 1 PELOD-2 score in survivors and non-survivors
PELOD-2 score PEdiatric Logistic Organ Dysfunction-2 score, IQR interquartile 
range
Day Survivors Non‑survivors p
Mean Median (IQR) Mean Median (IQR)
Day 1 6.7 7 (5;9) 11.2 10 (7;15) <0.001
Day 2 6.5 7 (4;9) 11.0 11 (8;13) <0.001
Day 5 6.1 6 (3;9) 9.2 9 (8;11) <0.001
Day 8 5.6 5 (3;8) 8.8 9 (7;11) <0.001
Day 12 5.1 5 (2;7) 8.5 9 (6;11) <0.001
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this lower discrimination, as observational studies have 
suggested that plasma transfusions were independently 
associated with increased risk of morbidity and mor-
tality [9, 22–24], but neither coagulopathy nor plasma 
transfusions are items of the PELOD-2 score. Third, 
except for mechanical ventilation, PELOD-2 score does 
not take into account the support that can be offered for 
each organ, such as vasoactive drugs, continuous renal 
replacement therapies, or extracorporeal life support 
(ECLS). Given that the mortality rate associated with 
ECLS is close to 50 % [25, 26], one could hypothesize that 
a lower discrimination may be due at least partly to the 
fact that PELOD-2 score does not take this variable into 
account. Similarly, the PELOD-2 score does not incor-
porate coagulopathy, which might be associated with 
increased risk of bleeding or disseminated intravascular 
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Fig. 1 Boxplot of the PELOD-2 score on days 1, 2, 5, 8, and 12, among survivors (white) and non-survivors (gray). On each study day, PELOD-2 scores 
were significantly different between survivors and non-survivors
Table 2 Serial evaluation of  the change in  the daily PELOD-2 score from  day 1, adjusted for  baseline value (PELOD-2 
score on day 1)
Odds ratio (OR) for death is provided with a 95 % CI. The cumulative OR of death can be calculated as follows: (OR of PELOD-2 score on day 1)PELOD-2 score on day 1 × (OR 
of change in score from day 1 to specific day)PELOD-2 score on specific day – PELOD-2 score on day 1. For example, for a child whose score is 10 on day 1 and 6 on day 12 (change in 
score −4), the OR for death would be 1.3010 × 1.38−4 = 3.80
PELOD-2 score PEdiatric Logistic Organ Dysfunction-2 score, OR odds ratio
Variable Odds ratio 95 % CI p value
PELOD-2 score on day 1 1.30 1.22–1.39 <0.0001
Change in PELOD-2 score
 Day 1–day 2 1.33 1.21–1.47 <0.0001
 Day 1–day 5 1.26 1.15–1.39 <0.0001
 Day 1–day 8 1.28 1.15–1.43 <0.0001
 Day 1–day 12 1.38 1.20–1.58 <0.0001
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coagulopathy, which are also known to be associated with 
increased mortality [27].
As observed in the validation study, severity of illness is a 
major component to evaluate the performance of the daily 
PELOD-2 scores [10]. Therefore, in this study, the serial 
evaluation of the change in the daily PELOD-2 score has to 
be adjusted to the baseline value (PELOD-2 score on day 
1). Our results indicate that changes in the PELOD-2 score 
over time are also associated with changes in the probabil-
ity of death. These are important findings, as they validate 
the use of sequential measuring of the PELOD-2 score to 
assess clinical outcome. These results also highlight the 
relationship between organ failure and death.
Some limitations must be recognized. First, our results 
are only applicable to critically ill children requiring 
plasma transfusions and not to other PICU subpopula-
tions. Second, our study days were not days after admis-
sion but days after plasma transfusion. It is of note, 
however, that the median length of PICU stay before the 
first plasma transfusion was 1 day. Third, although scores 
have classically been evaluated by their association with 
mortality, they might still adequately describe the clinical 
situation related to organ failure, as it has solid physiologi-
cal basis and is clinically meaningful. Therefore, the abil-
ity of the PELOD-2 score to describe organ failure and its 
change over time might be more important that its abil-
ity to predict death. Fourth, additional variables to the 
PELOD-2 score could have been evaluated. Unfortunately, 
some interesting variables, such as platelet count, were 
not available in our database. However, adding the INR to 
the PELOD-2 score did not improve its performance.
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Fig. 2 Receiver operating characteristic (ROC) curve of the PELOD-2 
score on day 1. The area under the curve was 0.76 (95 % CI 0.71–0.81). 
The dashed line represents the reference line
Table 3 Performance of the PELOD-2 score according to study days
PELOD-2 score PEdiatric Logistic Organ Dysfunction-2 score, IQR interquartile range, AUC area under receiver the operating characteristic curve
Day 1 Day 2 Day 5 Day 8 Day 12
Number of patients 443 411 295 231 165
Mortality rate 119 (27 %) 98 (24 %) 67 (23 %) 51 (22 %) 41 (25 %)
PELOD-2 (median, IQR) 7 (5;10) 7 (5;10) 7 (4;9) 6 (3;9) 6 (3;9)
AUC (95 % CI) 0.76 (0.71–0.81) 0.78 (0.73–0.84) 0.74 (0.67–0.81) 0.74 (0.66–0.82) 0.77 (0.68–0.85)
Hosmer–Lemeshow test p = 0.76 p = 0.63 p = 0.09 p = 0.30 p = 0.77
Table 4 Performance of the PELOD-2 score on day 1, according to indications to plasma transfusion
PELOD-2 score PEdiatric Logistic Organ Dysfunction-2 score, IQR interquartile range, AUC area under receiver the operating characteristic curve
a Preparation refers to preparation for surgery or procedure
Critical bleeding Minor Bleeding Preparationa Post‑op risk of bleeding No bleeding
Number of patients 99 94 52 47 151
Mortality rate 34 (35 %) 14 (16 %) 16 (32 %) 9 (19 %) 46 (31 %)
PELOD-2 (median, IQR) 8 (6–11) 7 (5–8) 7 (4–11) 7 (5–9) 7 (5–10)
AUC (95 % CI) 0.81 (0.72–0.91) 0.83 (0.70–0.96) 0.60 (0.44–0.76) 0.88 (0.74–1.00) 0.71 (0.62–0.80)
Hosmer–Lemeshow test p = 0.42 p = 0.34 p = 0.26 p = 0.54 p = 0.58
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Conclusions
In a subpopulation of critically ill children requiring 
plasma transfusion, the PELOD-2 score has a lower but 
acceptable discrimination than in an entire population. 
Although using this score as an outcome in a RCT seems 
reasonable, it should be interpreted cautiously.
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